Mutant p53 as a guardian of the cancer cell

被引:0
|
作者
Fiamma Mantovani
Licio Collavin
Giannino Del Sal
机构
[1] AREA Science Park,Laboratorio Nazionale CIB (LNCIB)
[2] Università degli Studi di Trieste,Dipartimento di Scienze della Vita
[3] IFOM—the FIRC Institute of Molecular Oncology,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Forty years of research have established that the p53 tumor suppressor provides a major barrier to neoplastic transformation and tumor progression by its unique ability to act as an extremely sensitive collector of stress inputs, and to coordinate a complex framework of diverse effector pathways and processes that protect cellular homeostasis and genome stability. Missense mutations in the TP53 gene are extremely widespread in human cancers and give rise to mutant p53 proteins that lose tumor suppressive activities, and some of which exert trans-dominant repression over the wild-type counterpart. Cancer cells acquire selective advantages by retaining mutant forms of the protein, which radically subvert the nature of the p53 pathway by promoting invasion, metastasis and chemoresistance. In this review, we consider available evidence suggesting that mutant p53 proteins can favor cancer cell survival and tumor progression by acting as homeostatic factors that sense and protect cancer cells from transformation-related stress stimuli, including DNA lesions, oxidative and proteotoxic stress, metabolic inbalance, interaction with the tumor microenvironment, and the immune system. These activities of mutant p53 may explain cancer cell addiction to this particular oncogene, and their study may disclose tumor vulnerabilities and synthetic lethalities that could be exploited for hitting tumors bearing missense TP53 mutations.
引用
收藏
页码:199 / 212
页数:13
相关论文
共 50 条
  • [31] Targeting mutant p53 for cancer therapy
    Oren, Moshe
    Tal, Perry
    Rotter, Varda
    AGING-US, 2016, 8 (06): : 1159 - 1160
  • [32] Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression
    Bossi, G
    Lapi, E
    Strano, S
    Rinaldo, C
    Blandino, G
    Sacchi, A
    ONCOGENE, 2006, 25 (02) : 304 - 309
  • [33] Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression
    G Bossi
    E Lapi
    S Strano
    C Rinaldo
    G Blandino
    A Sacchi
    Oncogene, 2006, 25 : 304 - 309
  • [34] A Chimeric p53 Evades Mutant p53 Transdominant Inhibition in Cancer Cells
    Okal, Abood
    Mossalam, Mohanad
    Matissek, Karina J.
    Dixon, Andrew S.
    Moos, Philip J.
    Lim, Carol S.
    MOLECULAR PHARMACEUTICS, 2013, 10 (10) : 3922 - 3933
  • [35] TRANSACTIVATION OF P53 IN P53 MUTANT-CELL LINES IN-VIVO
    PARK, DJ
    NAKAMURA, H
    CHUMAKOV, AM
    SAID, JW
    MILLER, CW
    CHEN, DL
    KOEFFLER, HP
    BLOOD, 1993, 82 (10) : A39 - A39
  • [36] Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line
    Lin, HY
    Shih, A
    Davis, FB
    Tang, HY
    Martino, LJ
    Bennett, JA
    Davis, PJ
    JOURNAL OF UROLOGY, 2002, 168 (02): : 748 - 755
  • [37] Genome guardian p53 and viral infections
    Sato, Yoshitaka
    Tsurumi, Tatsuya
    REVIEWS IN MEDICAL VIROLOGY, 2013, 23 (04) : 213 - 220
  • [38] Guardian of the Genome: p53 Tumor Suppressor
    Lubkeman, Kelly
    Palacio, Megan
    Wedel, Greta
    Delacruz, Kimy Hernandez
    Nguyen, Selina
    Alcaraz-Soto, Sheccid
    Szerdy, Sydney
    Fuentez, Tori
    Nunez, Oliver
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (03) : S689 - S689
  • [39] p53: Guardian of pancreatic epithelial identity
    Ghosh, Bidyut
    Leach, Steven D.
    CELL CYCLE, 2011, 10 (11) : 1717 - 1717
  • [40] TUMOR BIOLOGY - P53, GUARDIAN OF RB
    WHITE, E
    NATURE, 1994, 371 (6492) : 21 - 22